相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment of metastatic renal cell carcinoma and renal pelvic cancer
Nozomu Tanji et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2011)
Targeted-Therapy in Advanced Renal Cell Carcinoma
M. T. Pirrotta et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Update on targeted therapies for clear cell renal cell carcinoma
Eric A. Singer et al.
CURRENT OPINION IN ONCOLOGY (2011)
von Hippel-Lindau disease: A clinical and scientific review
Eamonn R. Maher et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
J. C. Welti et al.
ONCOGENE (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
Alfredo Carrato Mena et al.
ANTI-CANCER DRUGS (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Sunitinib for the management of advanced renal cell carcinoma
Bernard Escudier
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Camillo Porta et al.
KIDNEY INTERNATIONAL (2010)
Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels.
Aurelian Radu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas
Bernard Paule et al.
PLOS ONE (2010)
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas F. Kontovinis et al.
BMC CANCER (2009)
Combination Targeted Therapy in Advanced Renal Cell Carcinoma
Jeffrey Sosman et al.
CANCER (2009)
Role of the Phosphatidylinositol-3-Kinase and Extracellular Regulated Kinase Pathways in the Induction of Hypoxia-Inducible Factor (HIF)-1 Activity and the HIF-1 Target Vascular Endothelial Growth Factor in Ovarian Granulosa Cells in Response to Follicle-Stimulating Hormone
Hena Alam et al.
ENDOCRINOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
Edit Remak et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
Val R. Adams et al.
CLINICAL THERAPEUTICS (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
分享论文
